Preparation Process, Purity Analysis, and Compliance Management of Reagent-Grade IgG Products

I. Core Processes from Raw Materials to Reagent-Grade IgG

The production of reagent-grade IgG products typically uses human plasma, animal serum, or recombinant cell culture supernatant as the starting material. Different raw material sources determine the complexity of the purification process and the safety risks. Taking human plasma-derived IgG as an example, it generally requires cold ethanol precipitation, ion exchange chromatography, affinity chromatography, and viral inactivation/removal steps. Each step requires strict control of pH, conductivity, and flow rate to ensure the native conformation of the target protein and the function of the Fc fragment. In recent years, recombinant IgG technology has gradually matured, with the advantage of not relying on human plasma sources, thereby reducing the risk of bloodborne pathogen contamination at the source; however, production costs are higher, and attention must be paid to the impact of glycosylation modification differences on activity.

II. General Methods for Purity and Activity Analysis

Purity analysis often employs SDS-PAGE in tandem with high-performance liquid chromatography. SDS-PAGE can visually display heavy chain and light chain bands, while liquid chromatography is used to detect aggregates and degraded fragments. For activity, for reagent-grade IgG, ELISA is commonly used to determine its binding capacity to specific antigens, or surface plasmon resonance technology is used to calculate affinity constants. In addition, endotoxin testing and host protein residue testing are common items for the release of biological product raw materials. Since reagent-grade IgG is mostly used in detection systems rather than therapeutic purposes, microbial limit requirements may be relatively lenient, but it still needs to meet corresponding industry standards.

III. Regulatory and Quality Management System Requirements

In China, raw materials used for the production of in vitro diagnostic reagents need to comply with the traceability requirements of medical device or in vitro diagnostic reagent-related regulations. Although reagent-grade IgG itself may not be a registered product, as a key raw material, its supplier should pass quality management system audits. It is recommended that manufacturers prioritize suppliers with ISO 9001 or ISO 13485 certification and establish quality agreements with them. For imported products, certificates of origin, certificates of analysis, and stability data need to be provided. For reagent-grade IgG prepared in-house by laboratories, internal quality specifications and release processes should be established to ensure traceability between different batches.

IV. Industry Trends and Precautions

With the development of precision medicine and companion diagnostics, the requirements for the types and purity of reagent-grade IgG products are increasing. Some manufacturers have begun to offer IgG variants with removed Fc fragments or specific modifications to reduce detection background interference. In addition, animal-origin-free recombinant IgG is receiving more attention in immunoassays, especially for sample systems that need to avoid interference from human anti-mouse antibodies. When selecting reagent-grade IgG products, practitioners should combine regulatory changes and their own application scenarios, promptly update acceptance standards, and pay attention to supplier change notifications to avoid batch-to-batch differences caused by process adjustments affecting final detection results.